{"disease":{"id":"excess-abdominal-fat","name":"excess abdominal fat"},"drugs":{"marketed":[{"drug_id":"tesamorelin","indication_name":"Reduction of excess abdominal fat in HIV lipodystrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TESAMORELIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02748928","title":"UltraShape Power for Abdominal Fat and Circumference Reduction","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"Syneron Medical","has_results":true},{"nct_id":"NCT03502473","title":"UltraShape Power Device for Fat Reduction in Flanks","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Syneron Medical","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}